The drug distributor will remain a value stock despite some perceived threats, including the White House's aim to restructure pharmaceutical pricing.
Beating earnings estimates quarter after quarter doesn't have much to do with long-term shareholder value.
Count the reasons why Apple's near-term financial future doesn't look too bright.
Investor relations professionals should prepare for what's eventually inevitable: a reversion to the mean for stock prices.
For CFOs wanting to understand investor behavior, here's an argument that Jeff Bezos is human, after all, and Amazon can't defy basic economic…
Will Elon Musk succeed with his strategy of wooing investors with promises for the future and one shiny new object after another?
Forget it. No one knows what the stock market will do in the short term, and if someone says they do, they're a liar.
If oil prices remain at current levels, at some point bond investors may no longer be willing to support the shrinking enterprise.
The idea that the online retail-distribution giant could overtake large entrenched drug distributors like McKesson is far-fetched.
A buy-low strategy would favor going all-in on General Electric, but Amazon may be a better bet, despite its ambivalence on earnings.